Investigating blood vessel parameters in delayed cerebral ischemia after brain hemorrhage
Predicting Delayed Cerebral Ischemia Using Micro- and Macrovascular Parameters in Subarachnoid Hemorrhage Patients
This study is trying to understand the causes of delayed brain damage after a brain bleed by looking at blood vessel changes and other markers in patients who have had a specific type of hemorrhage.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Maastricht University Medical Center Academic / other |
| Locations | 1 site (Maastricht) |
| Trial ID | NCT05483751 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the complex mechanisms behind delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH). It focuses on measuring glycocalyx parameters using side-stream darkfield imaging and blood sampling to analyze markers of glycocalyx shedding. The study will also assess Doppler waveform morphologies in patients with DCI. By understanding these factors, the research seeks to shed light on the multifactorial causes of DCI, which affects a significant number of aSAH patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have confirmed aneurysmal subarachnoid hemorrhage and can be included within 72 hours after the event.
Not a fit: Patients who are imminently dying, have other causes of subarachnoid hemorrhage, or have significant language barriers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of delayed cerebral ischemia, potentially reducing morbidity and mortality in affected patients.
How similar studies have performed: While the specific approach of measuring glycocalyx parameters in this context is novel, previous studies have indicated the importance of microvascular factors in delayed cerebral ischemia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years * confirmed aneurysmal subarachnoid hemorrhage on CTA or DSA * inclusion within 72 hours after ictus Exclusion Criteria: * imminent death within 24 hours * other causes of subarachnoid hemorrhage like AVM or trauma * language barrier * ophthalmic or oral trauma or infection * absent temporal bone window for TCD
Where this trial is running
Maastricht
- Maastricht University Medical Center — Maastricht, Netherlands (Recruiting)
Study contacts
- Study coordinator: Roel Haeren, MD, PhD
- Email: roel.haeren@mumc.nl
- Phone: +31433874041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.